1.6M+ Patient Diagnoses Enabled per week
Every moment matters when facing a cancer diagnosis. Leica Biosystems empowers healthcare professionals to quickly and reliably deliver accurate diagnoses, transforming anxiety into answers for millions of people worldwide.
1500+ Total Patents Worldwide at the end of 2020
Our innovation is fueled by R&D investment, driven by customer insight, and proven by a robust patent portfolio. We strive to realize our purpose, enabling clinicians to efficiently provide patients a highly confident diagnosis within 24-hours from biopsy.
3000+ Associates Worldwide
Continuous improvement drives our global experts. We know real breakthroughs come from inclusive teams that think big, learn from diverse perspectives, and focus on outcomes that matter.
Dr. Darren Treanor, MB, BSc (Computing), PhD, FRCPath
Director, National Pathology Imaging Co-operative, UK
Consultant Histopathologist, Leeds Teaching Hospitals NHS Trust, UK
Honorary Clinical Professor, University of Leeds, UK
Adjunct Professor in Digital Pathology, Linköping University, Sweden
“The Leica Biosystems team understand that standardisation and interoperability are vital for the adoption of digital pathology and development of artificial intelligence. We value their methodical and practical approach, helping pathology to become increasingly digital and advancing our work at the UK National Pathology Imaging Co-operative program.”
Dr. Sylvia L. Asa, MD, PhD
Consultant in Endocrine Pathology, University Hospitals Cleveland Medical Center
"Leica Biosystems products are reliable and high quality, and the company is realistic about what's required to transform traditional pathology to a digital, connected practice. I know I can count on them and trust they will be there to support me now and well into the future."
Dr. Eric Peltier
Président Directeur Général - PRAXEA-DIAGNOSTICS
Thanks to our partnership with Leica, we have access to instruments of the highest caliber. The whole approach is about the quality, traceability, and connectivity…It's a base to work on innovation and development relying on the know-how of the pathologist. We also want to develop other technologies associated with this basis. So, it can be digital pathology technologies based on artificial intelligence.
Professor Koichi Ohshima PhD MD
Department of Pathology, School of Medicine, Kurume University
"Thank you for the fine connective system from Leica Biosystems, the systems well match the pathology works and studies at Kurume University. Recently we have tried to do case studies with hematologists and hematopathologists from over 20 hospitals and universities, using the virtual slide systems. The virtual slides work well in the web meetings, allowing good communication with the hematologists and hematopathologists. We are looking forward to collaborating with Leica Biosystems with Digital Pathology in the future."
News & Promotions
Now Available: BOND-PRIME Staining Platform
Featuring brand new core technology enabling Universal Access, the BOND-PRIME can seamlessly adapt to your incoming workflow demands. Coupled with the ability to produce high quality, crisp, clean staining with an average IHC TAT of 90 minutes, transcend expectations for quality, timeliness, and diagnostic productivity.
For In Vitro Diagnostic Use